NASDAQ:AMPH Amphastar Pharmaceuticals (AMPH) Stock Price, News & Analysis $28.25 +0.14 (+0.50%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$28.26 +0.01 (+0.04%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Amphastar Pharmaceuticals Stock (NASDAQ:AMPH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AMPH alerts:Sign Up Key Stats Today's Range$27.79▼$28.7050-Day Range$23.62▼$29.7152-Week Range$16.65▼$31.00Volume497,439 shsAverage Volume505,311 shsMarket Capitalization$1.20 billionP/E Ratio10.54Dividend YieldN/APrice Target$23.33Consensus RatingReduce Company Overview Amphastar Pharmaceuticals is a biopharmaceutical company that develops, manufactures and markets generic and proprietary medicines, with a focus on products that can be technically challenging to produce. Its offerings include injectable, inhalation and intranasal medicines, as well as insulin active pharmaceutical ingredients. The company’s products include treatments and emergency medicines such as enoxaparin, glucagon and epinephrine products. Amphastar also markets BAQSIMI, a nasal powder used to treat severe low blood sugar, and Primatene MIST, an over-the-counter asthma inhaler. Founded in 1996 and headquartered in Rancho Cucamonga, California, Amphastar serves customers primarily in the United States and also reaches international markets through its operations and commercial relationships.AI Generated. May Contain Errors. Read More Amphastar Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks25th Percentile Overall ScoreAMPH MarketRank™: 1.251388888885 of 5 starsAmphastar Pharmaceuticals scored higher than 25% of companies evaluated by MarketBeat, and ranked 742nd out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.3 / 5Analyst RatingReduce Consensus RatingAmphastar Pharmaceuticals has received a consensus rating of Reduce. The company's average rating score is 1.88, and is based on no strong buy ratings, no buy ratings, 7 hold ratings, and 1 sell rating.Downside RiskAmphastar Pharmaceuticals has a consensus price target of $23.33, representing about 17.4% downside from its current price of $28.25.Amount of Analyst CoverageAmphastar Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Amphastar Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-2.61% Earnings GrowthEarnings for Amphastar Pharmaceuticals are expected to decrease by -2.61% in the coming year, from $2.68 to $2.61 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amphastar Pharmaceuticals is 12.90, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.26.Price to Earnings Ratio vs. SectorThe P/E ratio of Amphastar Pharmaceuticals is 12.90, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.53.Price to Earnings Growth RatioAmphastar Pharmaceuticals has a PEG Ratio of 5.69. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmphastar Pharmaceuticals has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.23% of the float of Amphastar Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmphastar Pharmaceuticals has a short interest ratio ("days to cover") of 11.34, which indicates bearish sentiment.Change versus previous monthShort interest in Amphastar Pharmaceuticals has recently decreased by 1.67%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAmphastar Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmphastar Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.66 News SentimentAmphastar Pharmaceuticals has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Amphastar Pharmaceuticals this week, compared to 4 articles on an average week.MarketBeat Follows3 people have added Amphastar Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Amphastar Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,232,836.00 in company stock.Percentage Held by Insiders29.60% of the stock of Amphastar Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.09% of the stock of Amphastar Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amphastar Pharmaceuticals' insider trading history. Receive AMPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMPH Stock News HeadlinesAmphastar Pharmaceuticals (AMPH) Stock Looks Reasonable As Earnings Stay CentralNovember 21 at 1:02 AM | finance.yahoo.comAmphastar Pharmaceuticals Insider Sold Shares Worth $329,890, According to a Recent SEC FilingNovember 19 at 1:00 AM | marketscreener.comMPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access for just $7. The specialized indicator shows when a stock is likely to "snap back," helping traders avoid buying at the peak. It can also flag when a stock may bounce off the bottom so you can time your entry. Run NVDA or any other popular AI stock through it before you place a trade.November 21 at 1:00 AM | Base Camp Trading (Ad)Is Amphastar Pharmaceuticals (AMPH) Fully Priced After Strong Q3 Earnings And Q4 Guidance?November 13, 2026 | finance.yahoo.comAmphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in LondonNovember 11, 2026 | prnewswire.comShould Earnings Beat Require Action From Amphastar Pharmaceuticals (AMPH) Investors?November 7, 2026 | finance.yahoo.comInsider Selling: Amphastar Pharmaceuticals (NASDAQ:AMPH) CFO Sells 12,631 Shares of Company StockNovember 7, 2026 | insidertrades.comAmphastar Pharmaceuticals, Inc. (AMPH) Q3 2026 Earnings Call TranscriptNovember 6, 2026 | seekingalpha.comSee More Headlines AMPH Stock Analysis - Frequently Asked Questions How have AMPH shares performed this year? Amphastar Pharmaceuticals' stock was trading at $26.78 at the start of the year. Since then, AMPH shares have increased by 5.5% and is now trading at $28.25. How were Amphastar Pharmaceuticals' earnings last quarter? Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) posted its earnings results on Thursday, November, 5th. The company reported $1.14 earnings per share for the quarter, beating analysts' consensus estimates of $0.86 by $0.28. The company had revenue of $207.61 million for the quarter, compared to analysts' expectations of $197.52 million. Amphastar Pharmaceuticals had a trailing twelve-month return on equity of 15.31% and a net margin of 13.27%. Read the conference call transcript. When did Amphastar Pharmaceuticals IPO? Amphastar Pharmaceuticals (AMPH) raised $88 million in an initial public offering (IPO) on Wednesday, June 25th 2014. The company issued 8,000,000 shares at $10.00-$12.00 per share. Who are Amphastar Pharmaceuticals' major shareholders? Top institutional investors of Amphastar Pharmaceuticals include State Street Corp (3.93%), American Century Companies Inc. (3.72%), Marshall Wace LLP (2.85%) and Goldman Sachs Group Inc. (1.40%). Insiders that own company stock include Mary Z Luo, Rong Zhou, William J Peters, Yakob Liawatidewi, Floyd F Petersen, Richard K Prins and Michael A Zasloff. View institutional ownership trends. How do I buy shares of Amphastar Pharmaceuticals? Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amphastar Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amphastar Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Broadcom (AVGO), Salesforce (CRM), Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK) and Super Micro Computer (SMCI). Company Calendar Last Earnings11/05/2026Today11/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 AMPH's financial health is in the Green zone, according to TradeSmith. AMPH has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:AMPH CIK1297184 Webwww.amphastar.com Phone(909) 980-9484Fax909-980-8296Employees1,976Year Founded1996Price Target and Rating Average Price Target for Amphastar Pharmaceuticals$23.33 High Price Target$30.00 Low Price Target$20.00 Potential Upside/Downside-17.4%Consensus RatingReduce Rating Score (0-4)1.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)$2.19 Trailing P/E Ratio10.54 Forward P/E Ratio10.82 P/E Growth5Net Income$98.09 million Net Margins13.27% Pretax Margin17.37% Return on Equity15.31% Return on Assets7.15% Debt Debt-to-Equity Ratio0.75 Current Ratio3.32 Quick Ratio2.36 Sales & Book Value Annual Sales$719.89 million Price / Sales1.67 Cash Flow$4.25 per share Price / Cash Flow6.64 Book Value$19.10 per share Price / Book1.48Miscellaneous Outstanding Shares42,650,000Free Float30,027,000Market Cap$1.20 billion OptionableOptionable Beta0.93 Social Links 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NASDAQ:AMPH) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amphastar Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amphastar Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.